|Last Updated: May 27, 2023 @ 9:13 am|
Factor II (Prothrombin) Gene Mutation
|Stability:||Ambient: Unacceptable; Refrigerated: 1 Month(s); Frozen: Unacceptable; Incubated: Unacceptable|
|Interpretive Data:||General Reference Range : negative |
Where appropriate, medical consultation and/or genetic counseling should be offered to patients to inform and explain the risk implications and genetic implications of these test results.
Patient DNA is assayed for the Prothrombin G20210A mutation by polymerase chain reaction (PCR) and MOLDI-TOF mass spectrometry technology. The product of PCR is detected on the Agena Bioscience MassARRAY system.
The expression of Factor II thrombophilia is impacted by coexisting genetic thrombophilic disorders, acquired thrombophilic disorders (eg, malignancy, hyperhomocysteinemia, high factor VIII levels), and circumstances including: pregnancy, oral contraceptive use, hormone replacement therapy, selective estrogen receptor modulators, travel, central venous catheters, surgery, and organ transplantation. The test result must be interpreted along with the patient's clinical history and other pertinent laboratory data.
Variant analyzed: c.97G>A (G20210A), previously referred to as Factor II Gene Mutation.
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date.
Updated test information can only be guaranteed by using this website.